Zacks Research Has Bearish Estimate for Omnicell Q2 Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Analysts at Zacks Research dropped their Q2 2026 earnings estimates for Omnicell in a report issued on Thursday, March 5th. Zacks Research analyst Team now expects that the company will earn $0.19 per share for the quarter, down from their prior forecast of $0.20. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.29 EPS and Q3 2027 earnings at $0.28 EPS.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). The company had revenue of $313.98 million during the quarter, compared to the consensus estimate of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period last year, the firm posted $0.60 EPS. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS.

Several other analysts have also issued reports on the stock. Wells Fargo & Company boosted their target price on shares of Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Benchmark increased their price target on shares of Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target on the stock in a research note on Wednesday, January 7th. Bank of America upgraded Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a research note on Wednesday, February 4th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $49.00 target price (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $54.50.

Omnicell Price Performance

NASDAQ OMCL opened at $39.83 on Monday. The company has a 50-day moving average price of $44.48 and a 200-day moving average price of $38.41. Omnicell has a 52 week low of $22.66 and a 52 week high of $55.00. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $1.81 billion, a P/E ratio of 996.00, a PEG ratio of 1.48 and a beta of 0.79.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of OMCL. Raymond James Financial Inc. purchased a new stake in Omnicell in the 2nd quarter worth $26,000. First Horizon Corp purchased a new position in shares of Omnicell in the third quarter valued at about $31,000. Farther Finance Advisors LLC boosted its stake in shares of Omnicell by 784.8% in the third quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock worth $36,000 after acquiring an additional 1,036 shares during the period. Clearstead Advisors LLC boosted its stake in shares of Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after acquiring an additional 1,218 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Omnicell during the fourth quarter worth about $58,000. Institutional investors own 97.70% of the company’s stock.

Insider Activity

In other news, EVP Corey J. Manley sold 6,106 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the sale, the executive vice president directly owned 91,674 shares of the company’s stock, valued at $4,574,532.60. This represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.52% of the stock is currently owned by company insiders.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.